Product
MVR-C5252
1 clinical trial
1 indication
Indication
Recurrent High Grade GliomaClinical trial
The PuMP Trial: "A Multistage Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 in Patients With Recurrent High-Grade Glioma"Status: Not yet recruiting, Estimated PCD: 2026-12-01